(a)
(b)
(c)
(d)
(e)
(f)
Figure 1: Dovitinib inhibited cell proliferation in a dose- and time-dependent manner. The breast cancer cell lines were treated with dovitinib at the indicated doses for 24 and 48 h, and cell viability was assessed by MTT assay. Points, mean; bars, SD (N = 3). ; . (a) HCC1937. (b) MCF-7. (c) MDA-MB-231. (d) MDA-MB-453. (e) MDA-MB-468. (f) SK-BR-3.